Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal fourth quarter ended March 31 was ¥49.76 per share, a decrease from ¥50.59 per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥173.1 million, a decrease from ¥176.3 million in the year-earlier period.
The normalized profit margin climbed to 3.9% from 3.9% in the year-earlier period.
Total revenue decreased on an annual basis to ¥4.40 billion from ¥4.51 billion, and total operating expenses fell on an annual basis to ¥4.14 billion from ¥4.24 billion.
Reported net income decreased 33.7% from the prior-year period to ¥136.0 million, or ¥39.09 per share, from ¥205.0 million, or ¥58.84 per share.
For the year, the company's normalized net income totaled ¥179.47 per share, a gain of 21.9% from ¥147.24 per share in the prior year.
Normalized net income was ¥624.4 million, a rise of 11.6% from ¥559.4 million in the prior year.
Full-year total revenue grew on an annual basis to ¥17.53 billion from ¥17.17 billion, and total operating expenses grew on an annual basis to ¥16.55 billion from ¥16.30 billion.
The company said reported net income increased on an annual basis to ¥590.0 million, or ¥169.59 per share, in the full year, from ¥573.0 million, or ¥150.83 per share.
As of June 29, US$1 was equivalent to ¥102.64.